Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The Federal Institute for Drugs and Medical Devices of Germany (BrArM) and the Medicines and Healthcare products Regulatory Agency of the United Kingdom (MHRA) have approved Zogenix's and Desitin Pharmaceuticals' marketing authorization application (MAA) for Sumavel DosePro (sumatriptan injection) needle-free delivery system.
Subscribe to our email newsletter
Sumavel DosePro is indicated for the acute treatment of migraine attacks, with or without aura, and the acute treatment of cluster headache.
Sumavel DosePro is a pre-filled, single-use disposable, needle-free drug delivery system that subcutaneously delivers 6mg of sumatriptan in 0.5ml of sterile liquid.
Desitin Pharma is planning to introduce Sumavel DosePro in Denmark and Germany in early 2011.